View clinical trials related to Schizophrenia.
Filter by:The overarching aim of the proposed work is to align a promising treatment lead - Musical Intervention (MI) - with a promising mechanistic account of psychosis - Predictive Processing. The R61 phase (that this registration covers) will investigate the impact of group musical intervention on predictive processing metrics of hallucinations and social dysfunction.
The purpose of the study is to examine the effect of auricular acupressure on improvement of constipation and heart rate variability among residents with schizophrenia in community rehabilitation Center.The hypothesis of this study is that residents with schizophrenia in Community Rehabilitation Center receiving auricular acupressure can improve the symptoms of constipation and heart rate variability.By identifying the effectiveness of auricular acupressure can reduce the occurrence of constipation; suitable care can be suggested to improve gastrointestinal health in residents of Schizophrenia in community rehabilitation center.
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms. While drug therapy in schizophrenia targets positive symptoms; psychotherapies are needed in the treatment of negative symptoms. It is seen that especially art therapies such as occupational and music support recovery and rehabilitation. In addition, it is stated that dance and movement therapy is effective in ensuring social participation of patients. There are a limited number of studies demonstrating the effect of dance and movement therapy on schizophrenia patients. Aim: This project was planned to examine the effects of dance and movement therapy techniques to be applied to patients with schizophrenia on patients' negative symptoms and disability. Method: In this project, which was planned in a repetitive measure design with a pretest-posttest control group, dance and movement therapy techniques, consisting of 12 sessions in total, will be applied to schizophrenic patients in a Community Mental Health Center once a week. Negative symptoms and disability levels will be determined before, after and a month after the application. The findings obtained as a result of these three follow-ups will be evaluated. Project Outputs: Reduction of negative symptoms and disability will enable schizophrenic patients to become individuals who can express themselves better in their family and society and have an increased quality of life. It is thought that these gains will increase patients' compliance with treatment, prevent recurrent symptoms and reduce hospitalizations. The results will also constitute a scientific source for the studies to be carried out in the field.
CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: - how the body processes (uses) glucose (blood sugar) - how much insulin the pancreas can make. Insulin is a hormone that lowers blood sugar levels in the body. The information from this study will help to understand any effect the study medication may have on how the body uses and stores glucose. This study is accepting both male and female subjects. It will be held in approximately 6 locations in the United States. Participation could last up to 12 weeks.
The aim of this study is to evaluate schizophrenic patients who benefit from community mental health center services in terms of physical activity, physical fitness, and quality of life.
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of MK-8189 in participants with schizophrenia.
A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia. This study is accepting both male and female subjects. It will be conducted in approximately 6 study sites in the United States. The duration of participation will be approximtely 10 weeks.
The purpose of the study is to evaluate the feasibility of implementing cognitive training with 40 patients living with schizophrenia and schizoaffective disorder. The study aims to explore if cognitive training as an intervention can improve cognition, symptomology, social cognition, and psychosocial function which has been determined through literature to be impacted within this population. The results of this study will help shed light on utilizing additional resources to aid in decreasing relapse and continued hospitalizations.